Pharma company to lay off 427 at its N.J. headquarters
Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...
Purdue Pharma files new bankruptcy plan for $7.4 billion opioid settlement
Bankrupt drugmaker Purdue Pharma filed a new bankruptcy plan on Tuesday, a major step toward finalizing a proposed opioid ...
Fierce Pharma34 分钟
Purdue Pharma files new $7.4B bankruptcy reorganization plan to settle opioid claims
After a federal guilty plea in 2020, the former OxyContin drugmaker is required to reemerge from Chapter 11 bankruptcy as a ...
Today’s audio update: N.J. ban on deepfakes stalls out, big layoffs at pharma company ...
Hey there New Jersey! Here’s your audio update highlighting why Gov. Phil Murphy vetoed a bill that would have criminalized ...
Purdue Pharma Outlines Opioid Suit Settlement Plan That Includes Up To $7 Billion From ...
The new plan allows plaintiffs who sued Purdue to opt in to receive their settlement or reserve their right to file a civil ...
Purdue Pharma Files New Chapter 11 Plan in Bankruptcy Case
Purdue Pharma LP has filed a new Chapter 11 plan with the US Bankruptcy Court for the Southern District of New York, pledging ...
Daily Voice on MSN2 小时
Purdue Pharma Files New $7.4B Bankruptcy Plan: How Opioid Victims, Families Could Benefit
Purdue Pharma has filed a new bankruptcy plan that will distribute more than $7.4 billion to compensate opioid epidemic ...
Purdue Pharma submits opioid lawsuit settlement plan, including up to $7 billion cash from ...
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company and up to $7 billion in ...
Purdue Pharma files new bankruptcy plan to resolve opioid claims
Purdue Pharma on Wednesday filed a new Chapter 11 reorganization plan with the U.S. Bankruptcy Court for the Southern ...
The evolution of pharma marketing: How to reach consumers in the age of digital health
Pharma brands that fail to evolve risk losing relevance in a world where patients demand more control, transparency, and ...
Inozyme Pharma股价跌至52周新低，触及$0.98
Inozyme Pharma Inc. (INZY)股价跌至52周新低，触及$0.98，与其52周高点$7.79形成鲜明对比。根据 InvestingPro 分析，该公司目前正经历艰难时期，市值已降至约6700万美元。过去一年，Inozyme ...
Vincerx Pharma计划与QumulusAI进行反向并购
加利福尼亚州圣马特奥 - 目前股价为每股$0.83、市值186万美元的制药公司Vincerx Pharma, Inc. (NASDAQ: VINC )今日宣布计划与人工智能基础设施公司QumulusAI进行反向三角并购。此举将使QumulusAI成为一家上市公司。根据 InvestingPro 数据显示，Vincerx的流动比率为2.17，表明其短期财务状况稳健，为这一战略举措提供了良好基础。